MMJ International Holdings Shipping THC and CBD to US for Clinical Trials

MMJ International Holdings Shipping THC and CBD to US for Clinical Trials

Publication date: Aug 11, 2019

Most recently the FDA awarded MMJ International Holdings ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease.

The drugs, MMJ-001 and MMJ-002 are two of MMJ’s lead drugs that the company is confident will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease.

“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings.

Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receive gelatin capsules containing THC and CBD daily.

Concepts Keywords
API API
Bear Liquid encapsulation solutions
Boise Clinical trial
Canada Entheogens
Cannabis Euphoriants
Capsules Antiemetics
CBD Medicinal plants
CEO Tetrahydrocannabinol
CGMP Medical cannabis
Chronic Diseases Cannabis
Clinical Trials Health
DEA Articles
Drug Enforcement Agency Appetite stimulants
Drug Formulation MS
Elio Treatment diseases
Encapsulation Disease
FDA Product seizures
Gelatin Oral drug product
Huntington Manufacturing
Intellectual Property
Interstate Commerce
Marijuana
Multiple Sclerosis
Neurological Disorder
Orphan Drug
Pharmacological
PhD
Prescription Drug
Protocol
Seizures
THC
ThermoFisher Scientific
Treatment Modality

Semantics

Type Source Name
disease MESH multiple sclerosis
gene UNIPROT INPP5D
disease DOID multiple sclerosis
drug DRUGBANK Cannabidiol
drug DRUGBANK Coenzyme M
gene UNIPROT FHL5
disease MESH diagnosis
gene UNIPROT SERPINA3
gene UNIPROT ALG3
disease MESH seizures
gene UNIPROT NR4A2
disease MESH neurological disorder
disease MESH essential tremors
drug DRUGBANK Gelatin
gene UNIPROT TPI1
gene UNIPROT HAVCR1
gene UNIPROT TIMELESS
gene UNIPROT ARHGEF5
disease MESH chronic diseases
disease MESH suffering
gene UNIPROT RXFP2
gene UNIPROT PDC
drug DRUGBANK Alpha-1-proteinase inhibitor
disease MESH development
drug DRUGBANK Medical Cannabis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *